HK013 / HankeMab - LARVOL DELTA

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity. (PubMed, J Transl Med) - "The optimal anti-MSLN×4-1BB bsAb HK013-G1 exhibited synergistic antitumour effects by inducing an ADCC effect (innate immunity) and stimulating the 4-1BB signaling pathway (adaptive immunity) upon cross-bridging with MSLN with no systemic toxicity, which may offer the promise of an improved therapeutic window relative to that of 4-1BB agonists."

IO biomarker • Journal • Hepatology • Oncology • MSLN • MUC16 • TNFRSF9

Development of TSPO probe for the in situ detection of glioma (SNMMI 2024) - "68Ga-DOTA-HK-002, 68Ga-DOTA-HK-011, 68Ga-DOTA-HK-013 and 68Ga-DOTA-HK-015 were successfully synthesized and showed high radiochemical purity and stability. In comparison to 18F-FDG, it exhibits significantly enhanced absolute tumor uptake and retention, offering a more distinct visualization of the tumor contour and holding substantial promise for clinical translation."

Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

A novel MSLN×4–1BB bispecific antibody for solid tumor (SITC 2023) - "Moreover, HK013-G1 is well tolerated in cynomolgus monkeys. These results show that this bsAb has the potential to develop into a new clinical therapy for cancer types with high-level MSLN expression."

IO biomarker • Oncology • Solid Tumor • CD8 • IFNG • MSLN • TNFRSF9

Development of a novel MSLN×4-1BB bispecific antibody (AACR 2023) - "HK013-G1, a MSLN×4-1BB bsAb with human IgG1 Fc fragment prevents tumor development by killing tumor cells directly via effector functions mediated by NK and cytotoxic T cells. These results show that this bsAb has the potential to develop into a new clinical therapy for cancer types with high-level MSLN expression."

IO biomarker • Oncology • CD8 • IFNG • MSLN • TNFRSF9

A Novel anti-MSLN x 4-1BB bispecific antibody with Fc effect function augments the antitumor efficacy (SITC 2022) - "Compared with anti-4-1BB parent antibody and urelumab, HK013 induced weaker FcγR-mediated 4-1BB activation. Conclusions IgG1-based HK013-1 prevents tumor development by directly killing tumor cells and depleting Treg to relieve immunosuppression. Preclinical studies have shown that IgG1-based HK013-1 has good antitumor activity and safety, which may further develop its clinical potential."

Clinical • Bladder Cancer • Brain Cancer • Clear Cell Renal Cell Carcinoma • CNS Tumor • Genito-urinary Cancer • Glioblastoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • CD8 • IFNG • MSLN